{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:31:18Z","timestamp":1785522678325,"version":"3.56.0"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Biochem Biotechnol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s12010-026-05720-y","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T07:49:37Z","timestamp":1778744977000},"page":"5557-5582","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Decoding the Genetic Hallmarks of Breast Cancer: Molecular Signatures, Prognostic and Therapeutic Perspectives"],"prefix":"10.1007","volume":"198","author":[{"given":"Sahasra","family":"Allu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalini","family":"Saravanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunnathur Murugesan","family":"Sakthivel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathirvelan","family":"Chinnadurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavithra","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mythili","family":"Saravanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajan Radha","family":"Rasmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"issue":"2","key":"5720_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4103\/2231-4040.72251","volume":"1","author":"GN Sharma","year":"2010","unstructured":"Sharma, G. N., Dave, R., Sanadya, J., Sharma, P., & Sharma, K. K. (2010). Various types and management of breast cancer: An overview. Journal of Advanced Pharmaceutical Technology & Research, 1(2), 109\u2013126.","journal-title":"Journal of Advanced Pharmaceutical Technology &amp; Research"},{"issue":"6","key":"5720_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"5","key":"5720_CR3","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/87876","volume":"7","author":"KN Nathanson","year":"2001","unstructured":"Nathanson, K. N., Wooster, R., & Weber, B. L. (2001). Breast cancer genetics: What we know and what we need. Nature Medicine, 7(5), 552\u2013556. https:\/\/doi.org\/10.1038\/87876","journal-title":"Nature Medicine"},{"issue":"10","key":"5720_CR4","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s10552-006-0071-1","volume":"17","author":"L Titus-Ernstoff","year":"2006","unstructured":"Titus-Ernstoff, L., Tosteson, A. N., Kasales, C., Weiss, J., Goodrich, M., Hatch, E. E., Barlow, W. E., & Kerlikowske, K. (2006). Breast cancer risk factors in relation to breast density (United States). Cancer Causes & Control, 17(10), 1281\u20131290. https:\/\/doi.org\/10.1007\/s10552-006-0071-1","journal-title":"Cancer Causes & Control"},{"issue":"4","key":"5720_CR5","doi-asserted-by":"publisher","first-page":"5748","DOI":"10.18632\/aging.202502","volume":"13","author":"J Huang","year":"2021","unstructured":"Huang, J., Chan, P. S., Lok, V., Chen, X., Ding, H., Jin, Y., Yuan, J., Lao, X. Q., Zheng, Z. J., & Wong, M. C. S. (2021). Global incidence and mortality of breast cancer: A trend analysis. Aging (Albany NY), 13(4), 5748\u20135803. https:\/\/doi.org\/10.18632\/aging.202502","journal-title":"Aging (Albany NY)"},{"key":"5720_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold, M., Morgan, E., Rumgay, H., Mafra, A., Singh, D., Laversanne, M., Vignat, J., Gralow, J. R., Cardoso, F., Siesling, S., & Soerjomataram, I. (2022). Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast, 66, 15\u201323. https:\/\/doi.org\/10.1016\/j.breast.2022.08.010","journal-title":"Breast"},{"issue":"51","key":"5720_CR7","doi-asserted-by":"publisher","first-page":"21766","DOI":"10.1073\/pnas.0912499106","volume":"106","author":"AF Rubin","year":"2009","unstructured":"Rubin, A. F., & Green, P. (2009). Mutation patterns in cancer genomes. Proceedings of the National Academy of Sciences of the United States of America, 106(51), 21766\u201321770. https:\/\/doi.org\/10.1073\/pnas.0912499106","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"7283","key":"5720_CR8","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/nature08768","volume":"463","author":"GR Bignell","year":"2010","unstructured":"Bignell, G. R., Greenman, C. D., Davies, H., Butler, A. P., Edkins, S., Andrews, J. M., Buck, G., Chen, L., Beare, D., Latimer, C., Widaa, S., Hinton, J., Faulkner, A., Fu, B., Deloukas, P., Yang, F., Campbell, P. J., Futreal, P. A., & Stratton, M. R. (2010). Signatures of mutation and selection in the cancer genome. Nature, 463(7283), 893\u2013898. https:\/\/doi.org\/10.1038\/nature08768","journal-title":"Nature"},{"issue":"6417","key":"5720_CR9","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1126\/science.aau3879","volume":"362","author":"I Martincorena","year":"2018","unstructured":"Martincorena, I., Fowler, J. C., Wabik, A., Lawson, A. R. J., Abascal, F., Hall, M. W., Cagan, A., Murai, K., Mahbubani, K., Stratton, M. R., Fitzgerald, R. C., & Campbell, P. J. (2018). Somatic mutant clones colonize the human esophagus with age. Science, 362(6417), 911\u2013917. https:\/\/doi.org\/10.1126\/science.aau3879","journal-title":"Science"},{"issue":"Suppl 1","key":"5720_CR10","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.3978\/j.issn.2072-1439.2013.05.24","volume":"5","author":"HA Assi","year":"2013","unstructured":"Assi, H. A., Khoury, K. E., Dbouk, H., Khalil, L. E., Mouhieddine, T. H., & Saghir, E., N. S (2013). Epidemiology and prognosis of breast cancer in young women. Journal of Thoracic Disease, 5(Suppl 1), S2\u2013S8. https:\/\/doi.org\/10.3978\/j.issn.2072-1439.2013.05.24","journal-title":"Journal of Thoracic Disease"},{"key":"5720_CR11","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1590\/S0104-07072012000400031","volume":"21","author":"LM Rosa","year":"2012","unstructured":"Rosa, L. M., & Rad\u00fcnz, V. (2012). Survival rates to woman with breast cancer. Texto & Contexto - Enfermagem, 21, 980\u2013989.","journal-title":"Texto & Contexto - Enfermagem"},{"issue":"6","key":"5720_CR12","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1634\/theoncologist.9-6-606","volume":"9","author":"M Cianfrocca","year":"2004","unstructured":"Cianfrocca, M., & Goldstein, L. J. (2004). Prognostic and predictive factors in early-stage breast cancer. The Oncologist, 9(6), 606\u2013616. https:\/\/doi.org\/10.1634\/theoncologist.9-6-606","journal-title":"The Oncologist"},{"issue":"4","key":"5720_CR13","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/cncr.10742","volume":"95","author":"JS Michaelson","year":"2002","unstructured":"Michaelson, J. S., Silverstein, M., Wyatt, J., Weber, G., Moore, R., Halpern, E., & Kopans, D. B. (2002). Predicting the survival of patients with breast carcinoma using tumor size. Cancer, 95(4), 713\u2013723. https:\/\/doi.org\/10.1002\/cncr.10742","journal-title":"Cancer"},{"issue":"4","key":"5720_CR14","doi-asserted-by":"publisher","first-page":"R245","DOI":"10.1677\/ERC-10-0136","volume":"17","author":"MT Weigel","year":"2010","unstructured":"Weigel, M. T., & Dowsett, M. (2010). Current and emerging biomarkers in breast cancer: Prognosis and prediction. Endocrine-Related Cancer, 17(4), R245\u2013R262. https:\/\/doi.org\/10.1677\/ERC-10-0136","journal-title":"Endocrine-Related Cancer"},{"key":"5720_CR15","doi-asserted-by":"publisher","unstructured":"Manna, S., & Holz, M. K. (2016). Tamoxifen action in ER-negative breast cancer. Signal Transduction Insights, 5. https:\/\/doi.org\/10.4137\/STI.S29901.STI.S29901","DOI":"10.4137\/STI.S29901.STI.S29901"},{"issue":"3","key":"5720_CR16","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74(3), 229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"5","key":"5720_CR17","doi-asserted-by":"publisher","first-page":"515","DOI":"10.6004\/jnccn.2019.7307","volume":"17","author":"HH Cheng","year":"2019","unstructured":"Cheng, H. H., Sokolova, A. O., Schaeffer, E. M., Small, E. J., & Higano, C. S. (2019). Germline and somatic mutations in prostate cancer for the clinician. Journal of the National Comprehensive Cancer Network, 17(5), 515\u2013521. https:\/\/doi.org\/10.6004\/jnccn.2019.7307","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"1","key":"5720_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","volume":"10","author":"X Xiong","year":"2025","unstructured":"Xiong, X., Zheng, L. W., Ding, Y., Chen, Y. F., Cai, Y. W., Wang, L. P., Li, Y. Q., Zhang, J., Liu, Y., Huang, H., Zhou, X. Y., & Liu, Q. (2025). Breast cancer: Pathogenesis and treatments. Signal Transduction and Targeted Therapy, 10(1), 49. https:\/\/doi.org\/10.1038\/s41392-024-02108-4","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"11","key":"5720_CR19","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.7150\/ijbs.21635","volume":"13","author":"YS Sun","year":"2017","unstructured":"Sun, Y. S., Zhao, Z., Yang, Z. N., Xu, F., Lu, H. J., Zhu, Z. Y., Shi, W., Jiang, J., Yao, P. P., & Zhu, H. P. (2017). Risk factors and preventions of breast cancer. International Journal of Biological Sciences, 13(11), 1387\u20131397. https:\/\/doi.org\/10.7150\/ijbs.21635","journal-title":"International Journal of Biological Sciences"},{"issue":"5","key":"5720_CR20","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1913948","volume":"384","author":"Breast Cancer Association Consortium","year":"2021","unstructured":"Breast Cancer Association Consortium. (2021). Breast cancer risk genes\u2014association analysis in more than 113,000 women. New England Journal of Medicine, 384(5), 428\u2013439. https:\/\/doi.org\/10.1056\/NEJMoa1913948","journal-title":"New England Journal of Medicine"},{"issue":"9732","key":"5720_CR21","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1016\/S0140-6736(10)60636-8","volume":"375","author":"RC Travis","year":"2010","unstructured":"Travis, R. C., Reeves, G. K., Green, J., Bull, D., Tipper, S. J., Baker, K., Beral, V., Peto, R., Collins, R., Reeves, G. K., & Million Women Study Collaborators. (2010). Gene\u2013environment interactions in 7610 women with breast cancer: Prospective evidence from the Million Women Study. Lancet, 375(9732), 2143\u20132151. https:\/\/doi.org\/10.1016\/S0140-6736(10)60636-8","journal-title":"Lancet"},{"issue":"3","key":"5720_CR22","doi-asserted-by":"publisher","first-page":"e1003284","DOI":"10.1371\/journal.pgen.1003284","volume":"9","author":"S Nickels","year":"2013","unstructured":"Nickels, S., Truong, T., Hein, R., Stevens, K., Buck, K., Behrens, S., Eilber, U., Schmidt, M. K., van den Ouweland, A., Fasching, P. A., Beckmann, M. W., Hall, P., Czene, K., Liu, J., Meindl, A., Schmutzler, R. K., Flesch-Janys, D., & Chang-Claude, J. (2013). Evidence of gene\u2013environment interactions between common breast cancer susceptibility loci and established environmental risk factors. PLoS Genetics, 9(3), e1003284. https:\/\/doi.org\/10.1371\/journal.pgen.1003284","journal-title":"PLoS Genetics"},{"issue":"2","key":"5720_CR23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/bjc.2015.439","volume":"114","author":"A Rudolph","year":"2016","unstructured":"Rudolph, A., Chang-Claude, J., & Schmidt, M. K. (2016). Gene\u2013environment interaction and risk of breast cancer. British Journal of Cancer, 114(2), 125\u2013133. https:\/\/doi.org\/10.1038\/bjc.2015.439","journal-title":"British Journal of Cancer"},{"issue":"3","key":"5720_CR24","doi-asserted-by":"publisher","first-page":"237","DOI":"10.4161\/epi.23790","volume":"8","author":"E Hervouet","year":"2013","unstructured":"Hervouet, E., Cartron, P. F., Jouvenot, M., & Delage-Mourroux, R. (2013). Epigenetic regulation of estrogen signaling in breast cancer. Epigenetics, 8(3), 237\u2013245. https:\/\/doi.org\/10.4161\/epi.23790","journal-title":"Epigenetics"},{"issue":"1","key":"5720_CR25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/epigenomes7010006","volume":"7","author":"A Kim","year":"2023","unstructured":"Kim, A., Mo, K., Kwon, H., Choe, S., Park, M., Kwak, W., Kim, J., Lee, J., Park, J., & Kim, Y. (2023). Epigenetic regulation in breast cancer: Insights on epidrugs. Epigenomes, 7(1), 6. https:\/\/doi.org\/10.3390\/epigenomes7010006","journal-title":"Epigenomes"},{"issue":"5645","key":"5720_CR26","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.1088759","volume":"302","author":"MC King","year":"2003","unstructured":"King, M. C., Marks, J. H., & Mandell, J. B. (2003). Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science, 302(5645), 643\u2013646. https:\/\/doi.org\/10.1126\/science.1088759","journal-title":"Science"},{"issue":"1","key":"5720_CR27","doi-asserted-by":"publisher","first-page":"i","DOI":"10.1016\/S1042-3699(23)00083-3","volume":"36","author":"SR Chandra","year":"2024","unstructured":"Chandra, S. R., Nair, S., Woodis, K. M., Torales, L. D. G., Wolf, A., Britt, A., Patel, K., & Greene, A. K. (2024). Molecular, therapeutic, and surgical updates on head and neck vascular anomalies. Oral and Maxillofacial Surgery Clinics of North America, 36(1), i\u2013x.","journal-title":"Oral and Maxillofacial Surgery Clinics of North America"},{"issue":"66","key":"5720_CR28","first-page":"445","volume":"12","author":"SA Narod","year":"2011","unstructured":"Narod, S. A., & Salmena, L. (2011). BRCA1 and BRCA2 mutations and breast cancer. Discovery Medicine, 12(66), 445\u2013453.","journal-title":"Discovery Medicine"},{"issue":"13","key":"5720_CR29","doi-asserted-by":"publisher","first-page":"5795","DOI":"10.1093\/nar\/gks270","volume":"40","author":"L Krejci","year":"2012","unstructured":"Krejci, L., Altmannova, V., Spirek, M., & Zhao, X. (2012). Homologous recombination and its regulation. Nucleic Acids Research, 40(13), 5795\u20135818. https:\/\/doi.org\/10.1093\/nar\/gks270","journal-title":"Nucleic Acids Research"},{"issue":"4","key":"5720_CR30","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00018-005-5296-8","volume":"63","author":"L Kopfstein","year":"2006","unstructured":"Kopfstein, L., & Christofori, G. (2006). Metastasis: Cell-autonomous mechanisms versus contributions by the tumor microenvironment. Cellular and Molecular Life Sciences, 63(4), 449\u2013468. https:\/\/doi.org\/10.1007\/s00018-005-5296-8","journal-title":"Cellular and Molecular Life Sciences"},{"key":"5720_CR31","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3389\/fphar.2018.00909","volume":"9","author":"H Chen","year":"2018","unstructured":"Chen, H., Wu, J., Zhang, Z., Tang, Y., Li, X., & Liu, S. (2018). Association between BRCA status and triple-negative breast cancer: A meta-analysis. Frontiers in Pharmacology, 9, 909. https:\/\/doi.org\/10.3389\/fphar.2018.00909","journal-title":"Frontiers in Pharmacology"},{"key":"5720_CR32","unstructured":"Pulukuri, D. B., Penke, V. B., Palati, D. J., Pulla, P. R., Kalakotla, S., & Lolla, S. (2022). BRCA biological functions. In BRCA1 and BRCA2 Mutations\u2014Diagnostic and Therapeutic Implications. IntechOpen."},{"issue":"5","key":"5720_CR33","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/GIM.0b013e3181d38f2f","volume":"12","author":"N Petrucelli","year":"2010","unstructured":"Petrucelli, N., Daly, M. B., & Feldman, G. L. (2010). Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genetics in Medicine, 12(5), 245\u2013259. https:\/\/doi.org\/10.1097\/GIM.0b013e3181d38f2f","journal-title":"Genetics in Medicine"},{"issue":"6","key":"5720_CR34","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/PPO.0b013e318238f579","volume":"17","author":"KL Smith","year":"2011","unstructured":"Smith, K. L., & Isaacs, C. (2011). BRCA mutation testing in determining breast cancer therapy. Cancer Journal, 17(6), 492\u2013499. https:\/\/doi.org\/10.1097\/PPO.0b013e318238f579","journal-title":"Cancer Journal"},{"key":"5720_CR35","unstructured":"Petrucelli,N., Daly, M. B., & Pal, T. (2022). BRCA1- and BRCA2-associated hereditary breast and ovarian cancer. GeneReviews\u00ae. University of Washington. https:\/\/europepmc.org\/article\/NBK\/nbk1247"},{"issue":"5","key":"5720_CR36","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1001\/jamaoncol.2023.7322","volume":"10","author":"S Morganti","year":"2024","unstructured":"Morganti, S., Marra, A., De Angelis, C., Toss, A., Licata, L., Giugliano, F., Dieci, M. V., Conte, P., & Curigliano, G. (2024). PARP inhibitors for breast cancer treatment: A review. JAMA Oncology, 10(5), 658\u2013670. https:\/\/doi.org\/10.1001\/jamaoncol.2023.7322","journal-title":"JAMA Oncology"},{"key":"5720_CR37","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.dnarep.2018.08.021","volume":"71","author":"AD D\u2019Andrea","year":"2018","unstructured":"D\u2019Andrea, A. D. (2018). Mechanisms of PARP inhibitor sensitivity and resistance. Dna Repair, 71, 172\u2013176. https:\/\/doi.org\/10.1016\/j.dnarep.2018.08.021","journal-title":"Dna Repair"},{"issue":"6","key":"5720_CR38","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1080\/14737140.2018.1458613","volume":"18","author":"G Griguolo","year":"2018","unstructured":"Griguolo, G., Dieci, M. V., Guarneri, V., & Conte, P. (2018). Olaparib for the treatment of breast cancer. Expert Review of Anticancer Therapy, 18(6), 519\u2013530. https:\/\/doi.org\/10.1080\/14737140.2018.1458613","journal-title":"Expert Review of Anticancer Therapy"},{"key":"5720_CR39","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/978-3-319-91439-8_10","volume":"211","author":"S Bochum","year":"2018","unstructured":"Bochum, S., Berger, S., & Martens, U. M. (2018). Olaparib. Recent Results in Cancer Research, 211, 217\u2013233. https:\/\/doi.org\/10.1007\/978-3-319-91439-8_10","journal-title":"Recent Results in Cancer Research"},{"issue":"8","key":"5720_CR40","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gon\u00e7alves, A., Lee, K. H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., Roch\u00e9, H., Im, Y. H., Quek, R. G. W., Markova, D., Tudor, I. C., Hannah, A. L., Eiermann, W., & Blum, J. L. (2018). Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine, 379(8), 753\u2013763. https:\/\/doi.org\/10.1056\/NEJMoa1802905","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"5720_CR41","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1200\/JCO.19.01304","volume":"38","author":"JK Litton","year":"2020","unstructured":"Litton, J. K., Scoggins, M. E., Hess, K. R., Adrada, B. E., Murthy, R. K., Damodaran, S., Moulder, S. L., Thompson, A. M., Wickham-Garcia, E., Gonzalez-Angulo, A. M., Hortobagyi, G. N., & Buzdar, A. U. (2020). Neoadjuvant talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant. Journal of Clinical Oncology, 38(5), 388\u2013394. https:\/\/doi.org\/10.1200\/JCO.19.01304","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"5720_CR42","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3390\/genes12050727","volume":"12","author":"LS Stucci","year":"2021","unstructured":"Stucci, L. S., Intern\u00f2, V., Tucci, M., Perrone, M., Mannavola, F., Palmirotta, R., & Silvestris, F. (2021). The ATM gene in breast cancer: Its relevance in clinical practice. Genes, 12(5), 727. https:\/\/doi.org\/10.3390\/genes12050727","journal-title":"Genes"},{"issue":"4","key":"5720_CR43","doi-asserted-by":"publisher","first-page":"R73","DOI":"10.1186\/bcr2919","volume":"13","author":"DE Goldgar","year":"2011","unstructured":"Goldgar, D. E., Healey, S., Dowty, J. G., Da Silva, L., Chen, X., Spurdle, A. B., Chen, S., Yu, H., Barrowdale, D., Bolla, M. K., Wang, Q., Dennis, J., McGuffog, L., Healey, C. S., Stratton, M. R., & Easton, D. F. (2011). Rare variants in the ATM gene and risk of breast cancer. Breast Cancer Research, 13(4), R73. https:\/\/doi.org\/10.1186\/bcr2919","journal-title":"Breast Cancer Research"},{"issue":"5","key":"5720_CR44","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/gepi.21971","volume":"40","author":"M Marabelli","year":"2016","unstructured":"Marabelli, M., Cheng, S. C., & Parmigiani, G. (2016). Penetrance of ATM gene mutations in breast cancer: A meta-analysis of different measures of risk. Genetic Epidemiology, 40(5), 425\u2013431. https:\/\/doi.org\/10.1002\/gepi.21971","journal-title":"Genetic Epidemiology"},{"issue":"10","key":"5720_CR45","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1093\/hmg\/7.10.1555","volume":"7","author":"G Rotman","year":"1998","unstructured":"Rotman, G., & Shiloh, Y. (1998). ATM: From gene to function. Human Molecular Genetics, 7(10), 1555\u20131563. https:\/\/doi.org\/10.1093\/hmg\/7.10.1555","journal-title":"Human Molecular Genetics"},{"issue":"5","key":"5720_CR46","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3390\/genes9050241","volume":"9","author":"T Bordeira-Carrasco","year":"2018","unstructured":"Bordeira-Carrasco, T., S\u00e1, A., Lopes, J. M., Sobrinho-Sim\u00f5es, M., Soares, P., & Vinagre, J. (2018). Telomere maintenance mechanisms in cancer. Genes, 9(5), 241. https:\/\/doi.org\/10.3390\/genes9050241","journal-title":"Genes"},{"issue":"1","key":"5720_CR47","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3390\/ijms23010523","volume":"23","author":"S Ueno","year":"2022","unstructured":"Ueno, S., Sudo, T., & Hirasawa, A. (2022). ATM: Functions of ATM kinase and its relevance to hereditary tumors. International Journal of Molecular Sciences, 23(1), 523. https:\/\/doi.org\/10.3390\/ijms23010523","journal-title":"International Journal of Molecular Sciences"},{"issue":"8","key":"5720_CR48","doi-asserted-by":"publisher","first-page":"103662","DOI":"10.1016\/j.drudis.2023.103662","volume":"28","author":"B Priya","year":"2023","unstructured":"Priya, B., Ravi, S., & Kirubakaran, S. (2023). Targeting ATM and ATR for cancer therapeutics: Inhibitors in clinic. Drug Discovery Today, 28(8), 103662. https:\/\/doi.org\/10.1016\/j.drudis.2023.103662","journal-title":"Drug Discovery Today"},{"issue":"4","key":"5720_CR49","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41416-021-01405-x","volume":"125","author":"MR Middleton","year":"2021","unstructured":"Middleton, M. R., Dean, E., Evans, T. R., Shapiro, G. I., Pollard, J., Hendriks, B. S., Falk, M., Diaz-Padilla, I., Plummer, R., Dowlati, A., & Yap, T. A. (2021). Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine\u00b1cisplatin in patients with advanced solid tumours. British Journal of Cancer, 125(4), 510\u2013519. https:\/\/doi.org\/10.1038\/s41416-021-01405-x","journal-title":"British Journal of Cancer"},{"issue":"19","key":"5720_CR50","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1158\/1078-0432.CCR-21-1032","volume":"27","author":"TA Yap","year":"2021","unstructured":"Yap, T. A., Krebs, M. G., Postel-Vinay, S., El-Khoueiry, A., Soria, J. C., Lopez, J., Berges, A., Cheung, S. Y. A., Irurzun-Arana, I., Goldstein, L., Brown, J. S., Tunariu, N., & de Bono, J. S. (2021). Ceralasertib (AZD6738), an oral ATR kinase inhibitor, in combination with carboplatin in patients with advanced solid tumors: A phase I study. Clinical Cancer Research, 27(19), 5213\u20135224. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1032","journal-title":"Clinical Cancer Research"},{"issue":"6","key":"5720_CR51","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa1400382","volume":"371","author":"AC Antoniou","year":"2014","unstructured":"Antoniou, A. C., Casadei, S., Heikkinen, T., Barrowdale, D., Pylk\u00e4s, K., Roberts, J., Lee, A., Subramanian, D., De Leeneer, K., Fostira, F., Tomiak, E., Neuhausen, S. L., Engel, C., Nielsen, F. C., Taniguchi, T., Janavicius, R., Lubinski, J., Domchek, S. M., Nathanson, K. L., Couch, F. J., Easton, D. F., & King, M. C. (2014). Breast-cancer risk in families with mutations in PALB2. New England Journal of Medicine, 371(6), 497\u2013506. https:\/\/doi.org\/10.1056\/NEJMoa1400382","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"5720_CR52","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.3390\/ijms18091886","volume":"18","author":"TC Nepomuceno","year":"2017","unstructured":"Nepomuceno, T. C., De Gregoriis, G., Bastos de Oliveira, F. M., Suarez-Kurtz, G., Monteiro, A. N. A., & Carvalho, M. A. (2017). The role of PALB2 in the DNA damage response and cancer predisposition. International Journal of Molecular Sciences, 18(9), 1886. https:\/\/doi.org\/10.3390\/ijms18091886","journal-title":"International Journal of Molecular Sciences"},{"key":"5720_CR53","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3389\/fonc.2020.00301.eCollection2020","volume":"10","author":"S Wu","year":"2020","unstructured":"Wu, S., Zhou, J., Zhang, K., Chen, H., Luo, M., Lu, Y., Sun, S., Wang, Y., Chen, L., & Fan, S. (2020). Molecular mechanisms of PALB2 function and its role in breast cancer management. Frontiers in Oncology, 10, 301. https:\/\/doi.org\/10.3389\/fonc.2020.00301.eCollection2020","journal-title":"Frontiers in Oncology"},{"issue":"15_suppl","key":"5720_CR54","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS1109","volume":"39","author":"JJ Gruber","year":"2021","unstructured":"Gruber, J. J., Gross, W., McMillan, A., Ford, J. M., & Telli, M. L. (2021). A phase II clinical trial of talazoparib monotherapy for PALB2 mutation-associated advanced breast cancer. Journal of Clinical Oncology, 39(15_suppl), 1052. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.TPS1109","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"5720_CR55","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13058-019-1192-2","volume":"21","author":"C Mani","year":"2019","unstructured":"Mani, C., Jonnalagadda, S., Lingareddy, J., Awasthi, S., Gmeiner, W. H., & Palle, K. (2019). Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells. Breast Cancer Research, 21(1), 104. https:\/\/doi.org\/10.1186\/s13058-019-1192-2","journal-title":"Breast Cancer Research"},{"issue":"2","key":"5720_CR56","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/PAP.0000000000000015","volume":"21","author":"U Krishnamurti","year":"2014","unstructured":"Krishnamurti, U., & Silverman, J. F. (2014). HER2 in breast cancer: A review and update. Advances in Anatomic Pathology, 21(2), 100\u2013107. https:\/\/doi.org\/10.1097\/PAP.0000000000000015","journal-title":"Advances in Anatomic Pathology"},{"issue":"Suppl 2","key":"5720_CR57","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000055404","volume":"61","author":"S M\u00e9nard","year":"2001","unstructured":"M\u00e9nard, S., Fortis, S., Castiglioni, F., Agresti, R., & Balsari, A. (2001). HER2 as a prognostic factor in breast cancer. Oncology (Williston Park, N.Y.), 61(Suppl 2), 67\u201372. https:\/\/doi.org\/10.1159\/000055404","journal-title":"Oncology (Williston Park, N.Y.)"},{"issue":"24","key":"5720_CR58","doi-asserted-by":"publisher","first-page":"6034","DOI":"10.3390\/cancers14246034","volume":"14","author":"M Luque","year":"2022","unstructured":"Luque, M., Sanz-\u00c1lvarez, M., Morales-Gallego, M., Madoz-G\u00farpide, J., Zazo, S., Dom\u00ednguez, C., Eroles, P., Gomis, R. R., & Rojo, F. (2022). Tumor-infiltrating lymphocytes and immune response in HER2-positive breast cancer. Cancers, 14(24), 6034. https:\/\/doi.org\/10.3390\/cancers14246034","journal-title":"Cancers"},{"issue":"Suppl 1","key":"5720_CR59","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/annonc\/12.suppl_1.s3","volume":"12","author":"I Rubin","year":"2001","unstructured":"Rubin, I., & Yarden, Y. (2001). The basic biology of HER2. Annals of Oncology, 12(Suppl 1), S3\u2013S8. https:\/\/doi.org\/10.1093\/annonc\/12.suppl_1.s3","journal-title":"Annals of Oncology"},{"issue":"2","key":"5720_CR60","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E","volume":"182","author":"S Menard","year":"2000","unstructured":"Menard, S., Tagliabue, E., Campiglio, M., & Pupa, S. M. (2000). Role of HER2 gene overexpression in breast carcinoma. Journal of Cellular Physiology, 182(2), 150\u2013162. https:\/\/doi.org\/10.1002\/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E","journal-title":"Journal of Cellular Physiology"},{"issue":"6","key":"5720_CR61","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1093\/annonc\/mdl475","volume":"18","author":"G Valabrega","year":"2007","unstructured":"Valabrega, G., Montemurro, F., & Aglietta, M. (2007). Trastuzumab: Mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Annals of Oncology, 18(6), 977\u2013984. https:\/\/doi.org\/10.1093\/annonc\/mdl475","journal-title":"Annals of Oncology"},{"issue":"19","key":"5720_CR62","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D. Y., Di\u00e9ras, V., Guardino, E., Fang, L., Lu, M. W., Olsen, S., & Blackwell, K. (2012). Trastuzumab emtansine for HER2-positive advanced breast cancer. New England Journal of Medicine, 367(19), 1783\u20131791. https:\/\/doi.org\/10.1056\/NEJMoa1209124","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"5720_CR63","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/14712598.2021.1856812","volume":"21","author":"P Tarantino","year":"2021","unstructured":"Tarantino, P., Morganti, S., Uliano, J., Giugliano, F., Crimini, E., & Curigliano, G. (2021). Margetuximab for the treatment of HER2-positive metastatic breast cancer. Expert Opinion on Biological Therapy, 21(2), 127\u2013133. https:\/\/doi.org\/10.1080\/14712598.2021.1856812","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"2","key":"5720_CR64","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/annonc\/mds328","volume":"24","author":"M Capelan","year":"2013","unstructured":"Capelan, M., Pugliano, L., De Azambuja, E., Bozovic, I., Saini, K. S., Sotiriou, C., Piccart, M., & Di Leo, A. (2013). Pertuzumab: New hope for patients with HER2-positive breast cancer. Annals of Oncology, 24(2), 273\u2013282. https:\/\/doi.org\/10.1093\/annonc\/mds328","journal-title":"Annals of Oncology"},{"issue":"7","key":"5720_CR65","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","volume":"20","author":"RE Kontermann","year":"2015","unstructured":"Kontermann, R. E., & Brinkmann, U. (2015). Bispecific antibodies. Drug Discovery Today, 20(7), 838\u2013847. https:\/\/doi.org\/10.1016\/j.drudis.2015.02.008","journal-title":"Drug Discovery Today"},{"issue":"12","key":"5720_CR66","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","volume":"23","author":"F Meric-Bernstam","year":"2022","unstructured":"Meric-Bernstam, F., Beeram, M., Hamilton, E., Oh, D. Y., Hanna, D. L., Kang, Y. K., Elimova, E., Weise, A., Wildiers, H., Calles, A., Rha, S. Y., Lee, J., Park, Y. H., Sohn, J., Im, Y. H., Park, K., & Kang, W. K. (2022). Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: A phase 1, dose-escalation and expansion study. Lancet Oncology, 23(12), 1558\u20131570. https:\/\/doi.org\/10.1016\/S1470-2045(22)00621-0","journal-title":"Lancet Oncology"},{"key":"5720_CR67","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2147\/BCTT.S111394","volume":"9","author":"P Apostolou","year":"2017","unstructured":"Apostolou, P., & Papasotiriou, I. (2017). Current perspectives on CHEK2 mutations in breast cancer. Breast Cancer: Targets and Therapy, 9, 331\u2013335. https:\/\/doi.org\/10.2147\/BCTT.S111394","journal-title":"Breast Cancer: Targets and Therapy"},{"issue":"4","key":"5720_CR68","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/bies.20204","volume":"27","author":"A Traven","year":"2005","unstructured":"Traven, A., & Heierhorst, J. (2005). SQ\/TQ cluster domains: Concentrated ATM\/ATR kinase phosphorylation site regions in DNA-damage-response proteins. Bioessays, 27(4), 397\u2013407. https:\/\/doi.org\/10.1002\/bies.20204","journal-title":"Bioessays"},{"issue":"12","key":"5720_CR69","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1093\/hmg\/dds101","volume":"21","author":"W Roeb","year":"2012","unstructured":"Roeb, W., Higgins, J., & King, M. C. (2012). Response to DNA damage of CHEK2 missense mutations in familial breast cancer. Human Molecular Genetics, 21(12), 2738\u20132744. https:\/\/doi.org\/10.1093\/hmg\/dds101","journal-title":"Human Molecular Genetics"},{"issue":"2","key":"5720_CR70","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.cancergencyto.2010.07.124","volume":"202","author":"MD Iniesta","year":"2010","unstructured":"Iniesta, M. D., Gorin, M. A., Chien, L. C., Thomas, S. M., Milliron, K. J., Douglas, J. A., & Weitzel, J. N. (2010). Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America. Cancer Genetics and Cytogenetics, 202(2), 136\u2013140. https:\/\/doi.org\/10.1016\/j.cancergencyto.2010.07.124","journal-title":"Cancer Genetics and Cytogenetics"},{"issue":"9","key":"5720_CR71","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.trecan.2022.04.009","volume":"8","author":"RA Boonen","year":"2022","unstructured":"Boonen, R. A., Vreeswijk, M. P., & van Attikum, H. (2022). CHEK2 variants: Linking functional impact to cancer risk. Trends in Cancer, 8(9), 759\u2013770. https:\/\/doi.org\/10.1016\/j.trecan.2022.04.009","journal-title":"Trends in Cancer"},{"issue":"2","key":"5720_CR72","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1055\/s-0036-1579759","volume":"5","author":"H Correa","year":"2016","unstructured":"Correa, H. (2016). Li\u2013Fraumeni syndrome. Journal of Pediatric Genetics, 5(2), 84\u201388. https:\/\/doi.org\/10.1055\/s-0036-1579759","journal-title":"Journal of Pediatric Genetics"},{"issue":"43","key":"5720_CR73","doi-asserted-by":"publisher","first-page":"5912","DOI":"10.1038\/sj.onc.1209877","volume":"25","author":"H Nevanlinna","year":"2006","unstructured":"Nevanlinna, H., & Bartek, J. (2006). The CHEK2 gene and inherited breast cancer susceptibility. Trends in Cancer, 25(43), 5912\u20135919. https:\/\/doi.org\/10.1038\/sj.onc.1209877","journal-title":"Trends in Cancer"},{"issue":"4","key":"5720_CR74","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/ijc.20299","volume":"111","author":"O Kilpivaara","year":"2004","unstructured":"Kilpivaara, O., Vahteristo, P., Falck, J., Syrj\u00e4koski, K., Eerola, H., Easton, D. F., Pylk\u00e4s, K., Mantere, T., & Winqvist, R. (2004). CHEK2 variant I157T may be associated with increased breast cancer risk. International Journal of Cancer, 111(4), 543\u2013547. https:\/\/doi.org\/10.1002\/ijc.20299","journal-title":"International Journal of Cancer"},{"issue":"1","key":"5720_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yexcr.2004.10.016","volume":"304","author":"CC Ho","year":"2005","unstructured":"Ho, C. C., Siu, W. Y., Chow, J. P., Lau, A., Arooz, T., Tong, H. Y., Ng, I. O., & Poon, R. Y. (2005). The relative contribution of CHK1 and CHK2 to Adriamycin-induced checkpoint. Experimental Cell Research, 304(1), 1\u201315. https:\/\/doi.org\/10.1016\/j.yexcr.2004.10.016","journal-title":"Experimental Cell Research"},{"issue":"4","key":"5720_CR76","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.3892\/ol.2017.5792","volume":"13","author":"JS Kwon","year":"2010","unstructured":"Kwon, J. S., Gutierrez-Barrera, A. M., Young, D., Sun, C. C., Daniels, M. S., Lu, K. H., & Arun, B. K. (2010). CHK2 is involved in the p53-independent radiosensitizing effects of valproic acid. Oncology Letters, 13(4), 2591\u20132598. https:\/\/doi.org\/10.3892\/ol.2017.5792","journal-title":"Oncology Letters"},{"issue":"27","key":"5720_CR77","doi-asserted-by":"publisher","first-page":"4214","DOI":"10.1200\/JCO.2010.28.0719","volume":"28","author":"JS Kwon","year":"2010","unstructured":"Kwon, J. S., Gutierrez-Barrera, A. M., Young, D., Sun, C. C., Daniels, M. S., Lu, K. H., & Arun, B. K. (2010). Expanding the criteria for BRCA mutation testing in breast cancer survivors. Journal of Clinical Oncology, 28(27), 4214\u20134220. https:\/\/doi.org\/10.1200\/JCO.2010.28.0719","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"5720_CR78","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1200\/JCO.2005.01.9737","volume":"24","author":"PA James","year":"2006","unstructured":"James, P. A., Doherty, R., Harris, M., Mukesh, B. N., Milner, A., Young, M. A., & Phillips, K. A. (2006). Optimal selection of individuals for BRCA mutation testing: a comparison of available methods. Journal of Clinical Oncology, 24(4), 707\u2013715. https:\/\/doi.org\/10.1200\/JCO.2005.01.9737","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"5720_CR79","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s10549-013-2564-4","volume":"139","author":"S Biswas","year":"2013","unstructured":"Biswas, S., Atienza, P., Chipman, J., Hughes, K., Gutierrez-Barrera, A. M., Amos, C. I., & Arun, B. K. (2013). Simplifying clinical use of the genetic risk prediction model BRCAPRO. Breast Cancer Research and Treatment, 139(2), 571\u2013579. https:\/\/doi.org\/10.1007\/s10549-013-2564-4","journal-title":"Breast Cancer Research and Treatment"},{"issue":"3","key":"5720_CR80","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1148\/radiol.2019181814","volume":"291","author":"M Elezaby","year":"2019","unstructured":"Elezaby, M., Lees, B., Maturen, K. E., Barroilhet, L., Wisinski, K. B., Schrager, S., & Moy, L. (2019). BRCA mutation carriers: breast and ovarian cancer screening guidelines and imaging considerations. Radiology, 291(3), 554\u2013569. https:\/\/doi.org\/10.1148\/radiol.2019181814","journal-title":"Radiology"},{"key":"5720_CR81","doi-asserted-by":"publisher","unstructured":"National Comprehensive Cancer Network (2022). Genetic\/familial high-risk assessment: Breast and ovarian. NCCN Clinical Practice Guidelines in Oncology. Available at: https:\/\/doi.org\/10.6004\/jnccn.2021.0001","DOI":"10.6004\/jnccn.2021.0001"},{"issue":"3\u20134","key":"5720_CR82","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s10689-004-9552-0","volume":"3","author":"L Robles-D\u00edaz","year":"2004","unstructured":"Robles-D\u00edaz, L., Goldfrank, D. J., Kauff, N. D., Robson, M., & Offit, K. (2004). Hereditary ovarian cancer in Ashkenazi Jews. Familial Cancer, 3(3\u20134), 259\u2013264. https:\/\/doi.org\/10.1007\/s10689-004-9552-0","journal-title":"Familial Cancer"},{"issue":"2","key":"5720_CR83","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/jnci\/djn442","volume":"101","author":"TR Rebbeck","year":"2009","unstructured":"Rebbeck, T. R., Kauff, N. D., & Domchek, S. M. (2009). Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. Journal of the National Cancer Institute, 101(2), 80\u201387. https:\/\/doi.org\/10.1093\/jnci\/djn442","journal-title":"Journal of the National Cancer Institute"},{"issue":"3","key":"5720_CR84","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.cell.2012.01.014","volume":"148","author":"JE Dancey","year":"2012","unstructured":"Dancey, J. E., Bedard, P. L., Onetto, N., & Hudson, T. J. (2012). The genetic basis for cancer treatment decisions. Cell, 148(3), 409\u2013420. https:\/\/doi.org\/10.1016\/j.cell.2012.01.014","journal-title":"Cell"},{"key":"5720_CR85","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1146\/annurev.genom.9.081307.164359","volume":"9","author":"ER Mardis","year":"2008","unstructured":"Mardis, E. R. (2008). Next-generation DNA sequencing methods. Annual Review of Genomics and Human Genetics, 9, 387\u2013402. https:\/\/doi.org\/10.1146\/annurev.genom.9.081307.164359","journal-title":"Annual Review of Genomics and Human Genetics"},{"issue":"1\u20132","key":"5720_CR86","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0022-1759(01)00305-2","volume":"250","author":"M Yamamoto","year":"2001","unstructured":"Yamamoto, M., Wakatsuki, T., Hada, A., & Ryo, A. (2001). Use of serial analysis of gene expression (SAGE) technology. Journal of Immunological Methods, 250(1\u20132), 45\u201366. https:\/\/doi.org\/10.1016\/S0022-1759(01)00305-2","journal-title":"Journal of Immunological Methods"},{"issue":"12","key":"5720_CR87","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/nrd961","volume":"1","author":"A Butte","year":"2002","unstructured":"Butte, A. (2002). The use and analysis of microarray data. Nature Reviews Drug Discovery, 1(12), 951\u2013960. https:\/\/doi.org\/10.1038\/nrd961","journal-title":"Nature Reviews Drug Discovery"},{"issue":"1","key":"5720_CR88","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/00001622-200301000-00006","volume":"15","author":"H Hermeking","year":"2003","unstructured":"Hermeking, H. (2003). Serial analysis of gene expression and cancer. Current Opinion in Oncology, 15(1), 44\u201349. https:\/\/doi.org\/10.1097\/00001622-200301000-00006","journal-title":"Current Opinion in Oncology"},{"issue":"6","key":"5720_CR89","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1136\/archdischild-2013-304340","volume":"98","author":"S Behjati","year":"2013","unstructured":"Behjati, S., & Tarpey, P. S. (2013). What is next generation sequencing? Archives of disease in childhood. Education and Practice Edition, 98(6), 236\u2013238. https:\/\/doi.org\/10.1136\/archdischild-2013-304340","journal-title":"Education and Practice Edition"},{"key":"5720_CR90","doi-asserted-by":"publisher","unstructured":"Reis-Filho, J. S. (2009). Next-generation sequencing. Breast Cancer Research, 11(3). https:\/\/doi.org\/10.1186\/bcr2431","DOI":"10.1186\/bcr2431"},{"issue":"10","key":"5720_CR91","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/j.bbadis.2014.06.015","volume":"1842","author":"HP Buermans","year":"2014","unstructured":"Buermans, H. P., & den Dunnen, J. T. (2014). Next generation sequencing technology: advances and applications. Biochimica et Biophysica Acta, 1842(10), 1932\u20131941. https:\/\/doi.org\/10.1016\/j.bbadis.2014.06.015","journal-title":"Biochimica et Biophysica Acta"},{"issue":"1","key":"5720_CR92","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/jhg.2013.114","volume":"59","author":"B Rabbani","year":"2014","unstructured":"Rabbani, B., Tekin, M., & Mahdieh, N. (2014). The promise of whole-exome sequencing in medical genetics. Journal of Human Genetics, 59(1), 5\u201315. https:\/\/doi.org\/10.1038\/jhg.2013.114","journal-title":"Journal of Human Genetics"},{"key":"5720_CR93","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ejmech.2017.11.056","volume":"143","author":"I Ahmad","year":"2018","unstructured":"Ahmad, I. (2018). Tamoxifen a pioneering drug: An update on the therapeutic potential of tamoxifen derivatives. European Journal of Medicinal Chemistry, 143, 515\u2013531. https:\/\/doi.org\/10.1016\/j.ejmech.2017.11.056","journal-title":"European Journal of Medicinal Chemistry"},{"issue":"3","key":"5720_CR94","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41416-022-02023-4","volume":"128","author":"A Howell","year":"2023","unstructured":"Howell, A., & Howell, S. J. (2023). Tamoxifen evolution. British Journal of Cancer, 128(3), 421\u2013425. https:\/\/doi.org\/10.1038\/s41416-022-02023-4","journal-title":"British Journal of Cancer"},{"issue":"19","key":"5720_CR95","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1200\/JCO.18.01779","volume":"37","author":"A DeCensi","year":"2019","unstructured":"DeCensi, A., Puntoni, M., Guerrieri-Gonzaga, A., Caviglia, S., Avino, F., Cortesi, L., et al. (2019). Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia. Journal of Clinical Oncology, 37(19), 1629\u20131637. https:\/\/doi.org\/10.1200\/JCO.18.01779","journal-title":"Journal of Clinical Oncology"}],"container-title":["Applied Biochemistry and Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12010-026-05720-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12010-026-05720-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12010-026-05720-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:17:49Z","timestamp":1785518269000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12010-026-05720-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":95,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["5720"],"URL":"https:\/\/doi.org\/10.1007\/s12010-026-05720-y","relation":{},"ISSN":["0273-2289","1559-0291"],"issn-type":[{"value":"0273-2289","type":"print"},{"value":"1559-0291","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"2 May 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not Applicable.","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors agree to participate.","order":2,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors agree to publish.","order":3,"name":"Ethics","label":"Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":5,"name":"Ethics","label":"Clinical Trial Number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}